{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T12:57:11Z","timestamp":1701694631887},"reference-count":50,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T00:00:00Z","timestamp":1280966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust NZ J Obst Gynaeco"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:p>First\u2010line therapy of advanced ovarian cancer involves primary cytoreductive surgery and adjuvant systemic chemotherapy. Progression of incompletely resected disease or recurrence after cytoreduction is inevitable. The approach to second\u2010line treatment is ill\u2010defined and chemotherapy remains the conventional approach, with surgery being reserved in some patients to debulk or palliate symptoms. Increasing evidence suggests that secondary cytoreduction improves progression\u2010free and overall survival. This approach may be appropriate in selected patients. Intraperitoneal chemotherapy delivered in the adjuvant setting postoperatively has been shown to be more effective than systemic chemotherapy in advanced ovarian cancer after primary surgery. However, its use has not been well accepted and has not been adopted in secondary surgery. Hyperthermic intraperitoneal chemotherapy delivered intraoperatively during surgery has been of clinical interest and may prove to be efficacious and advantageous. The support of the gynaecological cancer medical and surgical community to embrace the efforts and assist in the recruitment of appropriate patients into randomised trials of first relapse recurrent ovarian cancer will provide answers to questions and establish evidence that would impact the care of ovarian cancer patients.<\/jats:p>","DOI":"10.1111\/j.1479-828x.2010.01209.x","type":"journal-article","created":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T15:03:44Z","timestamp":1281107024000},"page":"465-471","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Second\u2010line treatment of first relapse recurrent ovarian cancer"],"prefix":"10.1111","volume":"50","author":[{"given":"Terence C.","family":"CHUA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winston","family":"LIAUW","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"ROBERTSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"MORRIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,5]]},"reference":[{"key":"e_1_2_4_2_2","volume-title":"Ovarian Cancer in Australia: An Overview, 2006","author":"AIHW, NBCC","year":"2006"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj019"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.10.074"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2517"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13718-X"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1238"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.195"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-suppl_5-11"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.18.1534"},{"issue":"18","key":"e_1_2_4_11_2","article-title":"A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05\/EORTC 55955 trials)","volume":"27","author":"Rustin GJ","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0913"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi147"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6151"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.08.075"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008469212268"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.987"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1552"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2963"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61157-0"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5345"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1939"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0782"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.02.009"},{"key":"e_1_2_4_25_2","article-title":"Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study","volume":"28","author":"Burger RA","year":"2010","journal-title":"Meeting: 2010 ASCO Annual Meeting Citation J Clin Oncol"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1755"},{"key":"e_1_2_4_27_2","first-page":"1307","article-title":"Tumor size, sensitivity to therapy, and design of treatment schedules","volume":"61","author":"Norton L","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_4_28_2","first-page":"1727","article-title":"A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate","volume":"63","author":"Goldie JH","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(82)90115-9"},{"key":"e_1_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1248"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2002.tb04616.x"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.08.033"},{"key":"e_1_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951101)76:9<1606::AID-CNCR2820760917>3.0.CO;2-H"},{"key":"e_1_2_4_34_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9058-0"},{"key":"e_1_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0357-0"},{"key":"e_1_2_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21845"},{"key":"e_1_2_4_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22447"},{"key":"e_1_2_4_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1001"},{"key":"e_1_2_4_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"e_1_2_4_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.01100.x"},{"issue":"2","key":"e_1_2_4_41_2","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt JS","year":"1980","journal-title":"Cancer Res"},{"key":"e_1_2_4_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/02656730701455318"},{"key":"e_1_2_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-009-0667-4"},{"key":"e_1_2_4_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.187"},{"key":"e_1_2_4_45_2","author":"Bereder JM","year":"2008","journal-title":"HIPEC in Ovarian Cancer \u2013 French Experience"},{"key":"e_1_2_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.01.007"},{"key":"e_1_2_4_47_2","first-page":"27","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"100","author":"Walker JL","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(97)00250-4"},{"key":"e_1_2_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.03.002"},{"key":"e_1_2_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.07.058"},{"key":"e_1_2_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.11.007"}],"container-title":["Australian and New Zealand Journal of Obstetrics and Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1479-828X.2010.01209.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1479-828X.2010.01209.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:36:02Z","timestamp":1698791762000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1479-828X.2010.01209.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1479-828X.2010.01209.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1479-828x.2010.01209.x","archive":["Portico"],"relation":{},"ISSN":["0004-8666","1479-828X"],"issn-type":[{"value":"0004-8666","type":"print"},{"value":"1479-828X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,5]]},"assertion":[{"value":"2010-08-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}